# Herantis Pharma Oyj > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/herantispharma). ## Overview Herantis Pharma is a Helsinki-based clinical-stage biotechnology company focused on developing disease-modifying treatments for Parkinson's disease. Its core program, HER-096, is a small peptide designed for subcutaneous administration and intended to reach the brain through the blood-brain barrier. ## Products & services • HER-096 subcutaneous peptide therapy for Parkinson's disease • Clinical development of disease-modifying neurodegeneration treatments • Biomarker-driven phase 1 and phase 2 proof-of-concept studies • Preclinical and translational research around CDNF biology - **HER-096 clinical program** (85%) — Development of the lead peptide candidate HER-096 for Parkinson's disease. - **Research collaborations and grants** (15%) — Non-dilutive research funding and partnered development support. - HER-096 subcutaneous peptide therapy for Parkinson's disease - Clinical development of disease-modifying neurodegeneration treatments - Biomarker-driven phase 1 and phase 2 proof-of-concept studies - Preclinical and translational research around CDNF biology ## Customers Herantis does not sell a commercial product to mass-market end customers; its primary counterparties are clinical trial participants, research collaborators, and funding partners that support drug development. The eventual commercial customers would be neurologists, hospitals, and healthcare systems if HER-096 or related programs reach approval. In the current stage, value is created through clinical data generation, biomarker evidence, and partner-supported development. - **Clinical trial participants** (primary) — Healthy volunteers and Parkinson's patients enrolled to test safety, tolerability, PK, and biomarkers. - **Research funders** (secondary) — Public and private grant providers that finance development work and reduce dilution. - **Future healthcare providers** (emerging) — Neurologists, hospitals, and health systems that would prescribe or administer HER-096 if approved. - **Potential licensing partners** (emerging) — Pharma or biotech partners that may support later-stage development or commercialization. - Parkinson's disease patients enrolled in clinical trials - Healthy volunteers used in early safety studies - Research funders and grant-making organizations - Future neurologists, hospitals, and health systems - Potential licensing or development partners ## Geography Herantis is headquartered in Helsinki, Finland, and is listed on Nasdaq First North Helsinki. Its development work is international in nature because clinical studies, scientific collaborations, and future commercialization for Parkinson's disease are typically cross-border activities. The company also references European research funding, which ties part of its development base to the EU ecosystem. - Headquartered in Helsinki, Finland - Listed on Nasdaq First North Helsinki - Clinical development is international by nature - European grant funding supports research activity - Future market access would likely be multi-country ## Strategy Herantis' strategy centers on advancing HER-096 through clinical proof-of-concept, using biomarker data to strengthen the case for later-stage development. The company also relies on non-dilutive funding and selective equity financing to support expensive clinical work while preserving optionality for partnering. - **Progress HER-096 into phase 2 proof-of-concept** (short-term) — Later-stage human data is the key value inflection for a clinical-stage biotech. - **Strengthen the clinical and biomarker package** (short-term) — Robust biomarker evidence can improve differentiation and de-risk development. - **Secure funding for development** (short-term) — Clinical trials are capital intensive and require continuous financing. - **Preserve partnering optionality** (medium-term) — A stronger data package can improve future licensing or collaboration terms. - Advance HER-096 from phase 1 into phase 2 proof-of-concept - Use biomarker evidence to refine dose and clinical endpoints - Leverage non-dilutive Horizon Europe and research grants - Maintain development optionality through equity financing - Build a data package attractive for future partnering ## Risks Herantis is exposed to the core risks of clinical-stage drug development: trial failure, regulatory setbacks, and uncertainty over whether HER-096 will translate into a viable therapy. The company also depends on external financing and third-party research and manufacturing capabilities, which can affect timing, cost, and continuity of development. - **HER-096 clinical development risk** [critical] — The lead asset must continue to show safety, tolerability, and efficacy in humans. - **Financing risk** [high] — Clinical development requires recurring capital and the company may need additional funding. - **Regulatory and approval risk** [high] — Drug candidates can be delayed or rejected by regulators even after promising early data. - **Third-party dependency risk** [medium] — Trials, lab work, and manufacturing rely on external partners and vendors. - **Intellectual property risk** [high] — A small biotech's value depends heavily on protecting its lead asset and know-how. - Clinical trials may fail to show efficacy or acceptable safety - Regulatory approval is uncertain and can be delayed - Funding needs are ongoing and capital markets may be volatile - Development depends on third-party CROs and manufacturers - IP protection is critical for a single-asset biotech ## Accounting As a clinical-stage biotech, Herantis' reported results are driven mainly by R&D expense recognition, grant income, and financing transactions rather than product revenue. Investors should watch how clinical trial costs, grant funding, and share-based payments flow through the income statement, and how cash balances support ongoing development. Any future licensing or milestone arrangements would also require careful revenue recognition judgment. - **Research and development expense recognition** — Material for operating result and comparability across periods - **Grant accounting** — Affects other operating income and funding visibility - **Share-based payment accounting** — Can materially affect operating expenses - **Potential future licensing revenue** — Could affect timing and volatility of reported revenue - R&D expense timing reflects clinical and preclinical program spend - Grant income recognition depends on eligible research activity - Share-based payments can materially affect reported operating loss - No commercial revenue means results are development-stage driven - Future licensing deals would require IFRS 15 judgment --- *Last updated: 2026-08-11T04:04:53.130950+00:00*